Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ulocuplumab + nivolumab
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Ulocuplumab + nivolumab** is an investigational combination of two monoclonal antibodies for cancer immunotherapy. Ulocuplumab is a CXCR4 antagonist monoclonal antibody, and nivolumab is a programmed death-1 (PD-1) checkpoint inhibitor monoclonal antibody. The combination is designed to target two immune pathways: CXCR4, involved in immune cell trafficking and tumor microenvironment regulation, and PD-1, involved in immune checkpoint suppression. This regimen is being explored for safety, tolerability, and efficacy in advanced or metastatic solid tumors, including small cell lung cancer (SCLC) and pancreatic adenocarcinoma (PAC)[1][3][5][7].
- Other names
- ulocuplumab + nivolumab
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ulocuplumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ulocuplumab + nivolumab.